Tuberculosis MDR-TB & XDR-TB The 2008 Report
The Trends and Developments report presents a top-level overview of the drug phenomenon in Europe, covering drug supply, use and public health problems as well as drug policy and responses. Together with the online Statistical Bulletin and 30 Country Drug Reports, it makes up the 2019 European Drug ...Report package.
Available in different languages: http://www.emcdda.europa.eu/publications/edr/trends-developments/2019_en
more
Table of contents:
- Preface
- Introductory note and acknowledgements
- Commentary
- Chapter 1: Drug supply and the market
- Chapter 2: Drug use prevalence and trends
- Chapter 3: Drug-related harms and responses
- Annex: National data tables
Available in 24 languages on:
http://www.emcdd...a.europa.eu/publications/edr/trends-developments/2018
more
Sources: National Commitment and Policy Instrument, 2019
Eurosurveillance
Impact Factor 5.7
June 2015
www.eurosurveillance.org
Featuring a series of articles on HIV and STI epidemiology, prevention and control among MSM in Europe
10 years after the UN general assembly special session on drugs
Rapid review and case studies from Member States
Этот документ содержит техническое руководство для стран по мониторингу усилий, направленных на
профилактику и лечение ВИЧ-инфекции среди людей, употребляющих и...ъекционные наркотики (ЛУИН),
и определению амбициозных, но достижимых задач национального уровня для расширения всеобщего
доступа к услугам.
more
В настоящем кратком докладе анализируются последние данные о распространенности употребления
табака в Европейском регионе ВОЗ, взятые из доклада о глобальной та...бачной эпидемии за 2017 г., рассматриваются предшествующие аналогичные доклады начиная с 2008 г, а также достижения в деле реализации комплекса мер MPOWER в Европейском регионе. В качестве обоснования используются фактические данные, собранные в «Сборнике аргументов для борьбы против табака». Оценивается прогресс, достигнутый в Европейском регионе ВОЗ в реализации Дорожной карты действий с целью усиления мер по осуществлению Рамочной конвенции ВОЗ по борьбе против табака в Европейском регионе на 2015–2025 гг. (далее – Дорожная карта), и протяженность дальнейшего пути к достижению конечной цели.
more
The High-Level Panel on International Financial Accountability, Transparency and Integrity for Achieving the 2030 Agenda (FACTI Panel) was convened by the 74th President of United Nations General Assembly and the 75th President of the Economic and Social Council on 2 March 2020. The objective of the... FACTI Panel is to contribute to the overall efforts undertaken by Member States to implement the ambitious and transformational vision of the 2030 Agenda for Sustainable Development. It is mandated to review current challenges and trends related to financial accountability, transparency and integrity, and to make evidence-based recommendations to close remaining gaps in the international system.
more
The High-Level Panel on International Financial Accountability, Transparency and Integrity for Achieving the 2030 Agenda (FACTI Panel) was convened by the 74th President of United Nations General Assembly and the 75th President of the Economic and Social Council on 2 March 2020. The objective of the... FACTI Panel is to contribute to the overall efforts undertaken by Member States to implement the ambitious and transformational vision of the 2030 Agenda for Sustainable Development. It is mandated to review current challenges and trends related to financial accountability, transparency and integrity, and to make evidence-based recommendations to close remaining gaps in the international system.
more
Patients with diabetes are at increased risk of developing cardiovascular disease (CVD) with its manifestations of coronary artery disease (CAD), heart failure (HF), atrial fibrillation (AF), and stroke, as well as aortic and peripheral artery diseases. In addition, diabetes is a major risk factor f...or developing chronic kidney disease (CKD), which in itself is associated with developing CVD. The combination of diabetes with these cardio-renal comorbidities enhances the risk not only for cardiovascular (CV) events but also for CV and all-cause mortality. The current European Society of Cardiology (ESC) Guidelines on the management of cardiovascular disease in patients with diabetes are designed to guide prevention and management of the manifestations of CVD in patients with diabetes based on data published until end of January 2023. Over the last decade, the results of various large cardiovascular outcome trials (CVOTs) in patients with diabetes at high CV risk with novel glucose- lowering agents, such as sodium–glucose co-transporter-2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists (RAs), but also novel non-steroidal mineralocorticoid receptor antagonists (MRAs), such as finerenone have substantially expanded available therapeutic op-
tions, leading to numerous evidence-based recommendations for the management of this patient population.
more